Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward Alveyn

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Rheumatology (Oxford, England)|May 10, 2022
Worse outcomes linked to ethnicity for early inflammatory arthritis in England and Wales: a national cohort studyMaryam A Adas, Sam Norton, Sathiyaa Balachandran, et al.
Rheumatology (Oxford, England)|September 19, 2023
Occupational impacts of early inflammatory arthritis: results from the National Early Inflammatory Arthritis AuditKatie Bechman, Emma S Cook, Edward Alveyn, et al.
Vaccines|January 22, 2024
No Waning of Pneumococcal Vaccine Responses over Time in People with Inflammatory Arthritis: Findings from a Single Centre CohortDeepak Nagra, Katie Bechman, Mark D Russell, et al.
Rheumatology (Oxford, England)|June 4, 2024
Pneumococcal vaccine uptake in patients with inflammatory arthritis: a single centre cohort studyDeepak Nagra, Katie Bechman, Mark D Russell, et al.
Rheumatology (Oxford, England)|November 1, 2024
Temporal and regional variation in the use of biologic and targeted synthetic DMARDs for rheumatoid arthritis: a nationwide cohort studyMark D Russell, Zijing Yang, Niamh Dooley, et al.
Annals of the Rheumatic Diseases|May 29, 2023
JAK inhibitors and the risk of malignancy: a meta-analysis across disease indicationsMark D Russell, Christopher Stovin, Edward Alveyn, et al.
The Lancet. Rheumatology|October 18, 2024
Factors associated with biological and targeted synthetic disease-modifying antirheumatic drug initiation for rheumatoid arthritis in underserved patient groups in England and Wales, UK: a national cohort studyMark D Russell, Mark Gibson, Benjamin Zuckerman, et al.
The Lancet. Rheumatology|November 30, 2022
Incidence and management of inflammatory arthritis in England before and during the COVID-19 pandemic: a population-level cohort study using OpenSAFELYMark D Russell, James B Galloway, Colm D Andrews, et al.
Rheumatology (Oxford, England)|June 5, 2025
Risk of infection in patients with early inflammatory arthritis: results from a large UK prospective observational cohort studyMaryam A Adas, Katie Bechman, Mark D Russell, et al.
The Lancet. Rheumatology|January 22, 2024
Gout incidence and management during the COVID-19 pandemic in England, UK: a nationwide observational study using OpenSAFELYMark D Russell, Jon Massey, Edward Roddy, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Rheumatology (Oxford, England)|May 10, 2022
Worse outcomes linked to ethnicity for early inflammatory arthritis in England and Wales: a national cohort studyMaryam A Adas, Sam Norton, Sathiyaa Balachandran, et al.
Rheumatology (Oxford, England)|September 19, 2023
Occupational impacts of early inflammatory arthritis: results from the National Early Inflammatory Arthritis AuditKatie Bechman, Emma S Cook, Edward Alveyn, et al.
Vaccines|January 22, 2024
No Waning of Pneumococcal Vaccine Responses over Time in People with Inflammatory Arthritis: Findings from a Single Centre CohortDeepak Nagra, Katie Bechman, Mark D Russell, et al.
Rheumatology (Oxford, England)|June 4, 2024
Pneumococcal vaccine uptake in patients with inflammatory arthritis: a single centre cohort studyDeepak Nagra, Katie Bechman, Mark D Russell, et al.
Rheumatology (Oxford, England)|November 1, 2024
Temporal and regional variation in the use of biologic and targeted synthetic DMARDs for rheumatoid arthritis: a nationwide cohort studyMark D Russell, Zijing Yang, Niamh Dooley, et al.
Annals of the Rheumatic Diseases|May 29, 2023
JAK inhibitors and the risk of malignancy: a meta-analysis across disease indicationsMark D Russell, Christopher Stovin, Edward Alveyn, et al.
The Lancet. Rheumatology|October 18, 2024
Factors associated with biological and targeted synthetic disease-modifying antirheumatic drug initiation for rheumatoid arthritis in underserved patient groups in England and Wales, UK: a national cohort studyMark D Russell, Mark Gibson, Benjamin Zuckerman, et al.
The Lancet. Rheumatology|November 30, 2022
Incidence and management of inflammatory arthritis in England before and during the COVID-19 pandemic: a population-level cohort study using OpenSAFELYMark D Russell, James B Galloway, Colm D Andrews, et al.
Rheumatology (Oxford, England)|June 5, 2025
Risk of infection in patients with early inflammatory arthritis: results from a large UK prospective observational cohort studyMaryam A Adas, Katie Bechman, Mark D Russell, et al.
The Lancet. Rheumatology|January 22, 2024
Gout incidence and management during the COVID-19 pandemic in England, UK: a nationwide observational study using OpenSAFELYMark D Russell, Jon Massey, Edward Roddy, et al.
Pageof 3